Table 1.
Clinicopathologic features of patients in the 1990–2000 and 2007–2014 datasets*
| Characteristic | 1990–2000 | 2007–2014 | P |
|---|---|---|---|
| (n = 1320) | (n = 1095) | ||
| Age, y | 69 (59–76) | 65 (54–75) | <.0001 |
| Sex | .90 | ||
| Female | 664 (50%) | 554 (51%) | |
| Male | 656 (50%) | 541 (49%) | |
| Location | <.0001 | ||
| Right | 506 (38%) | 434 (40%) | |
| Transverse | 131 (10%) | 132 (12%) | |
| Left | 153 (12%) | 83 (8%) | |
| Sigmoid | 401 (30%) | 290 (26%) | |
| Rectosigmoid | 129 (10%) | 156 (14%) | |
| Differentiation | <.0001 | ||
| Well | 139 (11%) | 29 (3%) | |
| Moderate | 1011 (77%) | 884 (81%) | |
| Poor | 165 (13%) | 179 (16%) | |
| Lymphovascular invasion | 212 (16%) | 493 (46%) | <.0001 |
| Perineural invasion | 79 (6%) | 282 (26%) | <.0001 |
| T-stage | .019 | ||
| T1 | 230 (17%) | 159 (15%) | |
| T2 | 247 (19%) | 190 (17%) | |
| T3 | 743 (56%) | 630 (58%) | |
| T4 | 100 (8%) | 116 (11%) | |
| N-stage | .003 | ||
| N0 | 940 (71%) | 711 (65%) | |
| N1 | 271 (21%) | 265 (24%) | |
| N2 | 109 (8%) | 119 (11%) | |
| AJCC stage, fifth edition | .001 | ||
| I | 421 (32%) | 286 (26%) | |
| II | 520 (39%) | 425 (39%) | |
| III | 379 (29%) | 384 (35%) | |
| Preoperative CEA, ng/mL | 3.1 (1.7 – 6.7) | 3.1 (2 – 5.9) | .33 |
| range = 0.2– 798 | range = 0.4–210.6 | ||
| No. of positive nodes (N1/2) | 2 (1–4) | 2 (1–4) | .576 |
| No. of negative nodes | 13 (8–20) | 21 (16–29) | <.0001 |
| range = 0–146 | range = 2–78 | ||
| No. of lymph nodes evaluated | 14 (9 – 21) | 22 (17 – 30) | <.0001 |
| >12 lymph nodes evaluated | 807 (61%) | 1064 (97%) | <.0001 |
| Stage I | 187 (44%) | 271 (95%) | <.0001 |
| Stage II | 343 (66%) | 417 (98%) | <.0001 |
| Stage III | 277 (73%) | 376 (98%) | <.0001 |
| Postoperative chemotherapy | |||
| Stage I | 8 (2%) | 0 (0%) | .019 |
| Stage II | 72 (14%) | 107 (25%) | <.0001 |
| Stage III | 320 (85%) | 331 (89%) | .14 |
*Continuous data are presented as n (interquartile range), with ranges below when they differ, and categorical data as n (%). AJCC = American Joint Commission on Cancer; CEA = carcinoembryonic antigen.